Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,314 Cr.
- Current Price ₹ 596
- High / Low ₹ 737 / 469
- Stock P/E 35.2
- Book Value ₹ 109
- Dividend Yield 0.00 %
- ROCE 24.2 %
- ROE 20.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 67.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.1%
Cons
- Working capital days have increased from 97.7 days to 208 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | |
511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,305 | |
Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 534 |
OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% |
7 | -102 | -3 | -21 | 58 | 79 | 107 | |
Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 |
Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 |
Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 |
Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% |
14 | -12 | 149 | 163 | 266 | 337 | 407 | |
EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 19% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 67% |
3 Years: | 29% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 24% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 |
Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 |
147 | 483 | 51 | 66 | 502 | 490 | 102 | |
108 | 222 | 220 | 524 | 638 | 627 | 609 | |
Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
104 | 119 | 86 | 138 | 664 | 646 | 678 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 |
225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | |
Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
65 | 22 | 172 | 297 | 130 | 508 | 442 | |
-18 | -16 | -81 | -158 | -896 | -326 | -683 | |
-21 | 136 | -132 | 233 | 333 | -66 | 288 | |
Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 47 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 | 81 |
Inventory Days | |||||||
Days Payable | |||||||
Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 | 81 |
Working Capital Days | 23 | 64 | 53 | 16 | 45 | 40 | 208 |
ROCE % | 37% | 55% | 46% | 33% | 29% | 24% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 -
Change In Corporate Identity Number (CIN)
9h - Company's CIN changed post-IPO listing on 13 May 2024 from U73100KA1998PLC102040 to L73100KA1998PLC102040.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Indegene partners with Indian Institute of Cerebral Palsy to promote inclusivity and improve care.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 May - Indegene partners with ISPP to advance health policy research and design in India.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 May - Transcript of the conference call on financial results for the quarter and year ended March 31,2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Apr - Results for the quarter and financial year ended March 31,2025.
Concalls
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.